Drug firm Alembic Pharmaceuticals has received tentative approval from the US health regulator for Ticagrelor tablets, used to reduce the rate of cardiovascular death and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).
Quoting IQVIA sales data, the company said, Ticagrelor tablets, 90 mg had an estimated market size of USD 625 million for 12 months, ending December 2017.
The company said it now has a total of 75 ANDA approvals from the USFDA.
The company's stock was trading at Rs 540, up 1.71 per cent, on the BSE.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)